Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives $14.80 Consensus Price Target from Brokerages

Achieve Life Sciences, Inc. (NASDAQ:ACHV) has been given a consensus recommendation of “Buy” by the six brokerages that are covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $14.80.

Several equities research analysts have recently commented on the stock. Oppenheimer reissued an “outperform” rating and set a $11.00 target price on shares of Achieve Life Sciences in a research report on Thursday, August 15th. Raymond James initiated coverage on shares of Achieve Life Sciences in a research report on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 price objective for the company. Rodman & Renshaw initiated coverage on shares of Achieve Life Sciences in a research report on Thursday. They issued a “buy” rating and a $12.00 price objective for the company. Finally, RODMAN&RENSHAW raised shares of Achieve Life Sciences to a “strong-buy” rating in a research report on Thursday.

Institutional Trading of Achieve Life Sciences

A number of institutional investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of Achieve Life Sciences by 6.9% during the 3rd quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company’s stock valued at $3,552,000 after buying an additional 48,474 shares in the last quarter. Barclays PLC lifted its stake in shares of Achieve Life Sciences by 303.1% during the 3rd quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 35,832 shares in the last quarter. State Street Corp lifted its stake in Achieve Life Sciences by 6.8% in the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock worth $2,045,000 after purchasing an additional 27,419 shares in the last quarter. Verition Fund Management LLC purchased a new stake in Achieve Life Sciences in the 3rd quarter worth approximately $113,000. Finally, MetLife Investment Management LLC lifted its stake in Achieve Life Sciences by 65.6% in the 3rd quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 5,939 shares in the last quarter. 33.52% of the stock is currently owned by hedge funds and other institutional investors.

Achieve Life Sciences Trading Down 3.2 %

ACHV opened at $4.25 on Friday. Achieve Life Sciences has a 1-year low of $3.03 and a 1-year high of $5.98. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The company has a market cap of $146.16 million, a P/E ratio of -3.76 and a beta of 1.57. The company has a fifty day moving average price of $4.72 and a two-hundred day moving average price of $4.77.

Achieve Life Sciences (NASDAQ:ACHV) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same period in the prior year, the company earned ($0.34) EPS. Analysts predict that Achieve Life Sciences will post -1.17 EPS for the current fiscal year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.